

Christophe Guignabert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6484679/publications.pdf>

Version: 2024-02-01

167
papers

10,762
citations

34076

52
h-index

34964

98
g-index

178
all docs

178
docs citations

178
times ranked

9626
citing authors

#	ARTICLE	IF	CITATIONS
1	CRISPR/Cas9-mediated inactivation of the phosphatase activity of soluble epoxide hydrolase prevents obesity and cardiac ischemic injury. <i>Journal of Advanced Research</i> , 2023, 43, 163-174.	4.4	7
2	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. <i>Cardiovascular Research</i> , 2022, 118, 1805-1820.	1.8	26
3	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. <i>Chest</i> , 2022, 161, 219-231.	0.4	26
4	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 106-119.	0.6	17
5	Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 445-457.	0.3	12
6	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. <i>Arthritis Research and Therapy</i> , 2022, 24, 13.	1.6	6
7	Smooth muscle Rac1 contributes to pulmonary hypertension. <i>British Journal of Pharmacology</i> , 2022, 179, 3418-3429.	2.7	8
8	Driving Role of Interleukin-2-Related Regulatory CD4^+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 1387-1398.	2.9	13
9	Platelet-Derived Growth Factor Receptor Type β Activation Drives Pulmonary Vascular Remodeling Via Progenitor Cell Proliferation and Induces Pulmonary Hypertension. <i>Journal of the American Heart Association</i> , 2022, 11, e023021.	1.6	5
10	New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis. <i>Circulation Research</i> , 2022, 130, 1365-1381.	2.0	20
11	Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, , .	1.4	2
12	Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5227-5237.	1.1	7
13	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2021, 117, 1391-1401.	1.8	23
14	The Thousand Faces of Leptin in the Lung. <i>Chest</i> , 2021, 159, 239-248.	0.4	18
15	Targeting transforming growth factor- β receptors in pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002341.	3.1	67
16	Altered TGF- β /SMAD Signaling in Human and Rat Models of Pulmonary Hypertension: An Old Target Needs Attention. <i>Cells</i> , 2021, 10, 84.	1.8	16
17	The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. <i>Lancet Rheumatology</i> , The, 2021, 3, e149-e159.	2.2	11
18	Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling. <i>Thorax</i> , 2021, 76, 326-334.	2.7	13

#	ARTICLE	IF	CITATIONS
19	The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy. <i>Nature Reviews Cardiology</i> , 2021, 18, 565-580.	6.1	115
20	An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. <i>Nature Communications</i> , 2021, 12, 1720.	5.8	30
21	Pulmonary hypertension associated with neurofibromatosis type 2. <i>Pulmonary Circulation</i> , 2021, 11, 1-4.	0.8	0
22	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 58, 2000332.	3.1	28
23	Screening for pulmonary arterial hypertension in adults carrying a <i>BMPR2</i> mutation. <i>European Respiratory Journal</i> , 2021, 58, 2004229.	3.1	50
24	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. <i>Asvide</i> , 2021, 8, 298-298.	0.0	0
25	Role of Connexin 43 increased expression in pulmonary arterial hyperreactivity induced by the nerve growth factor NGF. , 2021, , .		0
26	Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?. <i>Metabolites</i> , 2021, 11, 784.	1.3	2
27	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. <i>Cardiovascular Research</i> , 2020, 116, 686-697.	1.8	54
28	Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 318, L1-L9.	1.3	13
29	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. <i>Cardiovascular Research</i> , 2020, 116, 885-893.	1.8	70
30	Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1900169.	3.1	12
31	Purinergic Dysfunction in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2020, 9, e017404.	1.6	16
32	Dendritic Cells in Pulmonary Hypertension: Foot Soldiers or Hidden Enemies?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 551-552.	1.4	2
33	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , 2020, 56, 2000279.	3.1	28
34	The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient. <i>Cells</i> , 2020, 9, 1422.	1.8	23
35	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. <i>European Respiratory Journal</i> , 2020, 56, 2001634.	3.1	284
36	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 766-782.	1.1	44

#	ARTICLE	IF	CITATIONS
37	Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2020, 9, 1248.	1.0	8
38	Dysfunction and Restoration of Endothelial Cell Communications in Pulmonary Arterial Hypertension: Therapeutic Implications. , 2020, , 147-155.		0
39	NGF induces pulmonary arterial hyperreactivity through connexin 43 increased expression. , 2020, , .		0
40	Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment?. , 2020, , .		0
41	Role of c-Abelson in the loss of genome integrity in endothelial cells in pulmonary arterial hypertension. , 2020, , .		0
42	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodeling in experimental pulmonary hypertension. , 2020, , .		0
43	Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models. , 2020, , .		0
44	Different tryptophan-kynurenine metabolism profiles in human pulmonary arterial hypertension and animal models of pulmonary hypertension. <i>European Heart Journal</i> , 2020, 41, .	1.0	1
45	Lower plasma melatonin levels predict worse long-term survival in pulmonary arterial hypertension. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
46	Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2019, 115, 432-439.	1.8	38
47	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. <i>European Respiratory Journal</i> , 2019, 54, 1802400.	3.1	25
48	PPAR γ Interaction with UBR5/ATMIN Promotes DNA Repair to Maintain Endothelial Homeostasis. <i>Cell Reports</i> , 2019, 26, 1333-1343.e7.	2.9	54
49	Response by Guignabert et al to Letter Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension". <i>Circulation Research</i> , 2019, 124, e82-e83.	2.0	2
50	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. <i>European Respiratory Journal</i> , 2019, 53, 1802472.	3.1	37
51	Lysyl oxidase—a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study. <i>Rheumatology</i> , 2019, 58, 1547-1555.	0.9	15
52	Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure. <i>Pulmonary Circulation</i> , 2019, 9, 1-15.	0.8	23
53	Functional interaction between PDGF β and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L445-L455.	1.3	12
54	Therapeutic effect of pifenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. <i>FASEB Journal</i> , 2019, 33, 3670-3679.	0.2	22

#	ARTICLE	IF	CITATIONS
55	Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. <i>Drug Discovery Today</i> , 2019, 24, 428-439.	3.2	74
56	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2019, 124, 846-855.	2.0	81
57	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. <i>European Respiratory Journal</i> , 2019, 53, 1801887.	3.1	776
58	Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic BMPR2 mutation carriers (DELPHI-2 Study). , 2019, , .		1
59	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2725-2736.	2.9	20
60	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. <i>European Respiratory Review</i> , 2018, 27, 180004.	3.0	21
61	Dasatinib increases endothelial permeability leading to pleural effusion. <i>European Respiratory Journal</i> , 2018, 51, 1701096.	3.1	50
62	Update in Pulmonary Vascular Disease 2016 and 2017. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 13-23.	2.5	6
63	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. <i>European Respiratory Journal</i> , 2018, 51, 1700745.	3.1	136
64	Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 910-924.	1.6	83
65	Editorial: Molecular Mechanisms in Pulmonary Hypertension and Right Ventricle Dysfunction. <i>Frontiers in Physiology</i> , 2018, 9, 1777.	1.3	1
66	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4105.	1.8	21
67	Loss-of-Function <i>ABCC8</i> Mutations in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002087.	1.6	62
68	T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 197.	1.6	40
69	Optimising experimental research in respiratory diseases: an ERS statement. <i>European Respiratory Journal</i> , 2018, 51, 1702133.	3.1	98
70	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 872-881.	0.4	43
71	ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. <i>European Respiratory Journal</i> , 2018, 51, 1800848.	3.1	34
72	Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension. <i>Frontiers in Physiology</i> , 2018, 9, 555.	1.3	21

#	ARTICLE	IF	CITATIONS
73	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 790-794.	1.0	5
74	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018, 128, 1956-1970.	3.9	125
75	Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model. , 2018, , .		1
76	OP0089â€¦Abatacept is effective in experimental digestive and lung tissue fibrosis. , 2018, , .		0
77	Pathophysiological mechanisms in pulmonary hypertension. , 2018, , 2487-2489.		0
78	Pulmonary vascular remodeling mediated by ADORA2B in pulmonary artery smooth muscle cells. , 2018, , .		0
79	Late Breaking Abstract - MIF inhibition in a murine model of bleomycin-induced lung fibrosis. , 2018, , .		0
80	Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension. <i>JACC Basic To Translational Science</i> , 2017, 2, 22-35.	1.9	31
81	Response to the article â€œSorafenib as a potential strategy for refractory pulmonary arterial hypertensionâ€. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 11-12.	1.1	3
82	Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 181-190.	1.5	34
83	Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 267-279.	1.3	42
84	Pathology and Pathobiology of Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 571-584.	0.8	33
85	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , 2017, 50, 1700217.	3.1	89
86	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2209-2221.	2.9	17
87	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1931-1940.	0.5	67
88	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 583-595.	2.5	113
89	A genome-wide association analysis identifies PDE1A DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population. <i>Oncotarget</i> , 2017, 8, 74917-74926.	0.8	15
90	New targets for pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 377-385.	1.2	16

#	ARTICLE	IF	CITATIONS
91	Dasatinib increases endothelial permeability leading to pleural effusion. , 2017, , .		0
92	Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model. , 2017, , .		0
93	Contribution of BMP9 to Pulmonary Arterial Hypertension. , 2017, , .		0
94	Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H604-H612.	1.5	13
95	<i>BMPR2</i> mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	3.1	68
96	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. European Respiratory Journal, 2016, 48, 1517-1519.	3.1	44
97	Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1410-1420.	2.5	77
98	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. Chest, 2016, 149, 1482-1493.	0.4	63
99	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	3.9	208
100	Changes in red blood cell membrane structure in pulmonary arterial hypertension. , 2016, , .		0
101	Uric acid causes excessive pulmonary arterial smooth muscle cell proliferation <i>via</i> URATv1 upregulation in pulmonary arterial hypertension. , 2016, , .		0
102	Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 342-355.	2.5	30
103	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2015, 46, 1211-1214.	3.1	5
104	Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. Reproductive Toxicology, 2015, 56, 45-51.	1.3	27
105	New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Chest, 2015, 147, 529-537.	0.4	140
106	Leptin signalling system as a target for pulmonary arterial hypertension therapy. European Respiratory Journal, 2015, 45, 1066-1080.	3.1	62
107	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 983-997.	2.5	144
108	Telomere Maintenance Is a Critical Determinant in the Physiopathology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2015, 66, 1942-1943.	1.2	9

#	ARTICLE	IF	CITATIONS
109	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 13-26.	1.0	27
110	Pathophysiology and Treatment of Pulmonary Arterial Hypertension. , 2015, , 949-974.		0
111	Hematopoietic Stem Cells and Chronic Hypoxia-Induced Pulmonary Vascular Remodelling. <i>Pancreatic Islet Biology</i> , 2015, , 241-256.	0.1	0
112	Time-resolved study of endothelial shear-responsiveness in pulmonary arterial hypertension. , 2015, , .		0
113	Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension. , 2015, , .		0
114	IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension. , 2015, , .		0
115	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscle-Like Cells in Pulmonary Hypertension. <i>Circulation</i> , 2014, 129, 1586-1597.	1.6	178
116	Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. <i>European Respiratory Journal</i> , 2014, 43, 641-643.	3.1	11
117	Protein Changes Contributing to Right Ventricular Cardiomyocyte Diastolic Dysfunction in Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2014, 3, e000716.	1.6	65
118	Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. <i>International Journal of Cancer</i> , 2014, 134, 765-777.	2.3	35
119	Angiomatoid fibrous histiocytoma of the pulmonary artery: a multidisciplinary discussion. <i>Histopathology</i> , 2014, 65, 278-282.	1.6	12
120	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
121	Contractile Dysfunction of Left Ventricular Cardiomyocytes in Patients With Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 64, 28-37.	1.2	82
122	Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2014, 115, 165-175.	2.0	708
123	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , 2014, 15, 65.	1.4	38
124	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 129, 1332-1340.	1.6	141
125	Reply: The Renin-Angiotensin System in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1139-1140.	2.5	0
126	Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D4-D12.	1.2	465

#	ARTICLE	IF	CITATIONS
127	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. <i>Nature Genetics</i> , 2013, 45, 518-521.	9.4	93
128	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. <i>European Respiratory Review</i> , 2013, 22, 543-551.	3.0	172
129	Pulmonary Alveolar Proteinosis Revealing a Telomerase Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 402-404.	2.5	11
130	Neurohormonal Axis in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 14-19.	2.5	85
131	Pathology and Pathobiology of Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 551-559.	0.8	100
132	Cellular microparticles in the pathogenesis of pulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 42, 272-279.	3.1	51
133	Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. <i>European Respiratory Journal</i> , 2013, 41, 3-4.	3.1	15
134	Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 714-724.	0.8	54
135	Right Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 2016-2025.	1.6	294
136	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 512-523.	1.6	97
137	Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension. <i>Handbook of Experimental Pharmacology</i> , 2013, 218, 409-436.	0.9	6
138	Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension. <i>Handbook of Experimental Pharmacology</i> , 2013, , 409-436.	0.9	7
139	Copper Dependence of Angioproliferation in Pulmonary Arterial Hypertension in Rats and Humans. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 46, 582-591.	1.4	46
140	A Critical Role for p130 ^{Cas} in the Progression of Pulmonary Hypertension in Humans and Rodents. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 666-676.	2.5	85
141	Dysregulated Renin-Angiotensin-Aldosterone System Contributes to Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 780-789.	2.5	309
142	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012, 40, 895-904.	3.1	110
143	The Therapeutic Potential Of The Renin-Angiotensin-Aldosteron System In Idiopathic Pulmonary Arterial Hypertension. , 2012, , .		1
144	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. <i>Circulation</i> , 2012, 125, 2128-2137.	1.6	548

#	ARTICLE	IF	CITATIONS
145	Inhibition of Transforming Growth Factor β 2 Worsens Elastin Degradation in a Murine Model of Kawasaki Disease. <i>American Journal of Pathology</i> , 2011, 178, 1210-1220.	1.9	19
146	Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 311-322.	1.4	125
147	Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22 β -targeted overexpression of the serotonin transporter. <i>FASEB Journal</i> , 2009, 23, 4135-4147.	0.2	80
148	Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. <i>European Respiratory Journal</i> , 2009, 34, 1100-1110.	3.1	68
149	RhoA and Rho Kinase Activation in Human Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1151-1158.	2.5	165
150	Tie2-mediated loss of peroxisome proliferator-activated receptor- β 3 in mice causes PDGF receptor- β 2-dependent pulmonary arterial muscularization. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L1082-L1090.	1.3	136
151	S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho β -Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. <i>Circulation Research</i> , 2009, 105, 639-647.	2.0	80
152	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. <i>Journal of Clinical Investigation</i> , 2009, 119, 512-523.	3.9	177
153	Developmental expression of LC3 β and β 2: Absence of fibronectin or autophagy phenotype in LC3 β knockout mice. <i>Developmental Dynamics</i> , 2008, 237, 187-195.	0.8	93
154	SM22 β -targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis. <i>Development (Cambridge)</i> , 2008, 135, 2981-2991.	1.2	58
155	Pulmonary arterial remodeling induced by a Th2 immune response. <i>Journal of Experimental Medicine</i> , 2008, 205, 361-372.	4.2	234
156	Smooth Muscle Protein 22 β -Mediated Patchy Deletion of <i>Bmpr1a</i> Impairs Cardiac Contractility but Protects Against Pulmonary Vascular Remodeling. <i>Circulation Research</i> , 2008, 102, 380-388.	2.0	43
157	Pulmonary arterial remodeling induced by a Th2 immune response. <i>Journal of Cell Biology</i> , 2008, 180, i9-i9.	2.3	1
158	An antiproliferative BMP-2/PPAR β /apoE axis in human and murine SMCs and its role in pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2008, 118, 1846-1857.	3.9	314
159	Dual Role for Plasminogen Activator Inhibitor Type 1 as Soluble and as Matricellular Regulator of Epithelial Alveolar Cell Wound Healing. <i>American Journal of Pathology</i> , 2006, 169, 1624-1632.	1.9	45
160	Vascular-wall remodeling of 3 human bypass vessels: Organ culture and smooth muscle cell properties. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 131, 651-658.	0.4	25
161	Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension. <i>Circulation</i> , 2006, 113, 1857-1864.	1.6	257
162	Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension. <i>Circulation Research</i> , 2006, 98, 1323-1330.	2.0	170

#	ARTICLE	IF	CITATIONS
163	Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 289, L67-L74.	1.3	53
164	Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats. Circulation, 2005, 111, 2812-2819.	1.6	200
165	Recurrence of Pulmonary Emphysema in an α 1-Proteinase Inhibitor-deficient Lung Transplant Recipient. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 811-814.	2.5	31
166	Interplay Between Serotonin Transporter Signaling and Voltage-Gated Potassium Channel (Kv) 1.5 Expression. , 0, , .		0
167	Erythrocytes are altered in pulmonary arterial hypertension. European Respiratory Journal, 0, , 2200506.	3.1	0